We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND...
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva...
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex...
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024...
Addex’s Partner Discontinues ADX71149 development in Epilepsy Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland...
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 3.02 | 3.02 | 3.02 | 7000 | 3.02 | DE |
4 | 0 | 0 | 3.02 | 3.02 | 3.02 | 1667 | 3.02 | DE |
12 | 0 | 0 | 3.02 | 3.02 | 3.02 | 574 | 3.02 | DE |
26 | 0 | 0 | 3.02 | 3.02 | 3.02 | 801 | 3.02 | DE |
52 | 0 | 0 | 3.02 | 3.02 | 3.02 | 1581 | 3.02 | DE |
156 | 0 | 0 | 3.02 | 3.02 | 3.02 | 949 | 3.02 | DE |
260 | 0 | 0 | 3.02 | 3.02 | 3.02 | 803 | 3.02 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions